Atrion Corporation (ATRI)
For informational purposes only. Not financial advice. Analysis by Sedat ANAK, Founder & Editor-in-Chief | AI-powered analysis. Data sourced from SEC filings and institutional-grade financial providers. Editorially reviewed. Not financial advice.
Atrion Corporation (ATRI) trades at $459.92 with AI Score 38/100 (Grade D). Atrion Corporation develops, manufactures, and sells medical devices and components for various medical applications. Market cap: $809.44M, Sector: Healthcare.
Price live · AI analysis from May 10, 2026Analyst Coverage for ATRI: ATRI does not currently have published analyst price targets in our coverage universe. This is common for smaller-cap names with limited Wall Street coverage. In the absence of analyst consensus, our AI model evaluates ATRI against Healthcare peers across nine fundamental dimensions and assigns an underweight signal based on the underlying data.
ATRI: 1/1 perspectives are bearish.
How is this calculated? →Atrion Corporation (ATRI) Healthcare & Pipeline Overview
Atrion Corporation specializes in developing and manufacturing medical devices and components for fluid delivery, cardiovascular, and ophthalmology applications. Operating globally, the company serves physicians, hospitals, and medical equipment manufacturers, distinguishing itself through specialized products and a direct sales approach within the healthcare sector.
What Is the Investment Thesis for ATRI?
Atrion Corporation presents a stable investment profile with a market capitalization of $809.44M and a P/E ratio of 41.7. The company's consistent profitability, reflected in a profit margin of 11.5% and a gross margin of 36.8%, underpins its financial health. A dividend yield of 1.91% offers investors a steady income stream. Growth catalysts include expansion into new therapeutic areas and increased adoption of its specialized medical devices. However, potential risks include competition from larger medical device manufacturers and regulatory changes in the healthcare sector. The company's beta of 0.69 suggests lower volatility compared to the broader market.
Based on FMP financials and quantitative analysis
ATRI Key Highlights
- Market capitalization of $809.44M indicates a solid presence in the medical device market.
- P/E ratio of 41.7 reflects investor expectations for future earnings growth.
- Profit margin of 11.5% demonstrates the company's ability to generate profits from its sales.
- Gross margin of 36.8% highlights efficient cost management in manufacturing and sales.
- Dividend yield of 1.91% provides a consistent income stream for investors.
Who Are ATRI's Competitors?
ATRI is benchmarked below against 8 industry peers on price, market cap, and our AI MoonshotScore.
| Company | Price | Change | Market Cap | AI Score |
|---|---|---|---|---|
| NYXH Nyxoah S.A. | $1.62 | -8.47% | $64.16M | 69 |
| KMTS Kestra Medical Technologies, Ltd. | $27.70 | +2.67% | $1.62B | 67 |
| ZTEK Zentek Ltd. | $0.46 | +2.88% | $49.90M | 63 |
| OMIC Singular Genomics Systems, Inc. | $20.01 | +0.00% | $50.77M | 61 |
| SARTF Sartorius AG | $212.80 | +0.00% | $14.69B | 51 |
| NSTG NanoString Technologies, Inc. | $0.11 | -37.43% | $5.07M | 51 |
| STAA STAAR Surgical Company | $27.45 | -1.21% | $1.37B | 51 |
| BLMHF Bloom Health Partners Inc. | $0.11 | +0.00% | $5.22M | 51 |
AI Score by Stock Expert AI · Price data: FMP / Yahoo Finance
What Are ATRI's Key Strengths?
- Specialized product portfolio
- Strong customer relationships
- Proprietary technologies
- Consistent profitability
What Are ATRI's Weaknesses?
- Limited brand recognition
- Dependence on key suppliers
- Geographic concentration
- High P/E ratio relative to peers
What Could Drive ATRI Stock Higher?
- Potential FDA approval for new cardiovascular device.
- Expansion of distribution network in Europe.
- Increased adoption of Myocardial Protection System in cardiac surgeries.
What Are the Key Risks for ATRI?
- Rich valuation — a P/E of 41.7 runs well above the Healthcare sector’s ~23x, leaving little room for a miss.
- Increased competition from larger medical device manufacturers.
- Regulatory changes impacting medical device approvals.
- Economic downturns affecting hospital budgets.
- Product liability claims related to medical devices.
What Are the Growth Opportunities for ATRI?
- Expansion into Emerging Markets: Atrion can leverage its existing product portfolio to penetrate emerging markets in Asia and Latin America. These regions are experiencing rapid growth in healthcare spending, creating significant demand for medical devices. A targeted market entry strategy, focusing on key countries with favorable regulatory environments, could drive substantial revenue growth. Timeline: Ongoing.
- New Product Development: Investing in research and development to create innovative medical devices for unmet clinical needs represents a significant growth opportunity. Focusing on areas such as minimally invasive surgery and remote patient monitoring could position Atrion as a leader in these emerging fields. Successful product launches would enhance the company's competitive advantage and drive long-term growth. Timeline: Ongoing.
- Strategic Acquisitions: Pursuing strategic acquisitions of smaller medical device companies with complementary technologies or product lines can accelerate Atrion's growth. Acquisitions can provide access to new markets, expand the company's product portfolio, and enhance its technological capabilities. Careful due diligence and integration are essential for successful acquisitions. Timeline: Ongoing.
- Increased Focus on Cardiovascular Products: Given the rising prevalence of cardiovascular diseases globally, Atrion can capitalize on this trend by expanding its cardiovascular product offerings. This includes developing advanced devices for heart failure management, cardiac rhythm management, and vascular interventions. Increased investment in this area could drive significant revenue growth. Timeline: Ongoing.
- Enhanced Distribution Channels: Strengthening its distribution channels through partnerships with leading medical distributors and hospitals can improve Atrion's market reach. This includes expanding its direct sales force and leveraging digital marketing strategies to reach a wider customer base. Enhanced distribution capabilities can drive increased sales and market share. Timeline: Ongoing.
What Opportunities Does ATRI Have?
- Expansion into emerging markets
- New product development
- Strategic acquisitions
- Increased focus on cardiovascular products
What Threats Does ATRI Face?
- Competition from larger medical device companies
- Regulatory changes
- Economic downturns
- Product liability claims
What Are ATRI's Competitive Advantages?
- Specialized product portfolio focused on niche markets.
- Strong relationships with physicians and hospitals.
- Proprietary technologies and intellectual property.
- Stringent regulatory approvals and compliance.
What Does ATRI Do?
Founded in 1944 and headquartered in Allen, Texas, Atrion Corporation develops, manufactures, and sells a range of medical devices and components. The company's product portfolio is diverse, spanning fluid delivery, cardiovascular, and ophthalmology applications. Atrion's fluid delivery products include specialized valves used in anesthesia and oncology, aiding in precise fluid and gas control. In the cardiovascular segment, the company offers the Myocardial Protection System, cardiac surgery vacuum relief valves, and inflation devices. For ophthalmology, Atrion provides medical devices for contact lens disinfection and balloon catheters for treating nasolacrimal duct obstruction. Beyond these core areas, Atrion manufactures instrumentation for measuring blood clotting time and products for safe needle and scalpel containment. The company also produces components for marine and aviation safety products, including inflation systems and pressure relief valves. Atrion serves a global clientele, selling its products to physicians, hospitals, clinics, and other medical equipment manufacturers through a direct sales force, independent sales representatives, and distributors. This multifaceted approach has allowed Atrion to establish a solid position in the medical device market.
What Products and Services Does ATRI Offer?
- Develops specialized valves for fluid and gas control in medical applications.
- Manufactures the Myocardial Protection System for cardiovascular procedures.
- Produces balloon catheters for treating nasolacrimal duct obstruction.
- Creates instrumentation for measuring blood clotting time.
- Offers products for safe needle and scalpel blade containment.
- Manufactures components for marine and aviation safety products.
- Develops pressure relief valves for protecting sensitive electronics during transport.
How Does ATRI Make Money?
- Develops and manufactures medical devices and components.
- Sells products directly to physicians, hospitals, and clinics.
- Utilizes independent sales representatives and distributors.
- Generates revenue through product sales and service contracts.
What Industry Does ATRI Operate In?
Atrion Corporation operates within the medical device industry, a sector characterized by continuous innovation and stringent regulatory oversight. The global medical device market is projected to reach trillions of dollars by 2026, driven by an aging population and increasing demand for advanced medical technologies. Atrion competes with both large, diversified medical device companies and smaller, specialized firms. The company's focus on niche markets and specialized products allows it to maintain a competitive edge.
Who Are ATRI's Key Customers?
- Physicians
- Hospitals
- Clinics
- Other medical equipment manufacturers
F-Score 6/9Financial Health
Atrion Corporation's Piotroski F-Score is 6/9, a 9-point checklist of profitability, leverage and efficiency — a middling fundamental profile. Its Altman Z-Score of 25.99 places it in the safe zone, indicating low near-term bankruptcy risk.
ROE 8%Key Financial Metrics
Return on equity for Atrion Corporation stands at 8.0%, a gauge of how efficiently it converts shareholder capital into profit. Return on assets is 7.4%, showing how much profit it generates from its asset base. ATRI trades at a trailing price-to-earnings ratio of 41.72, above the Healthcare sector average of ~23x. Its free cash flow yield is -0.3%, a gauge of the cash the business throws off relative to its market value. A current ratio of 9.09 indicates the company holds enough short-term assets to cover its near-term obligations. Its earnings yield is 2.4%, the inverse of the P/E and a quick read on earnings relative to price.
Atrion Corporation (ATRI) Valuation Context
Valued at $809.44M, ATRI is classified as a small-cap stock. Relative to its peer group, ATRI's quantitative score of 38/100 is below the peer average of 62/100.
ATRI Revenue & Earnings Trend
In Q2 2024, ATRI generated $48.8M in top-line revenue, marking a sequential increase of 3.0%. The company recorded net income of $402K, with diluted EPS of $0.23.
Company Profile
Atrion Corporation operates in the Medical - Instruments & Supplies industry within the Healthcare sector. It is headquartered in Allen, US. The company is led by CEO David A. Battat. ATRI has traded publicly since 1980.
ATRI Financials
Fundamental Snapshot
Based on FMP financials and quantitative analysis
Bull Case vs Bear Case
Bull Case
- Recent insider buying suggests those in the know see value, a potential sign of confidence in Atrion's future prospects.
- The community seems to be buzzing about potential new partnerships, hinting at growth opportunities for Atrion.
- Atrion's consistent dividend payouts are attracting income-focused investors, creating a stable base of support.
- Positive chatter around Atrion's strategic acquisitions indicates market approval of their expansion strategy.
Bear Case
- Increased short selling activity raises concerns that some investors anticipate a downturn in Atrion's performance.
- The community is worried about increasing competition in Atrion's sector, potentially impacting market share.
- Negative sentiment stemming from a recent regulatory change could create headwinds for Atrion's operations.
- Concerns are circulating regarding supply chain vulnerabilities, which could disrupt Atrion's production and profitability.
AI-generated arguments based on insider flow, news sentiment and technicals — not financial advice · February 2026
Recent Quarterly Results
| Quarter | Revenue | Net Income | EPS |
|---|---|---|---|
| Q2 2024 | $49M | $402,000 | $0.23 |
| Q1 2024 | $47M | $3M | $1.59 |
Based on FMP financials and quantitative analysis
ATRI Latest News
No recent news available for ATRI.
ATRI Analyst Consensus
Consensus Rating
Aggregated Buy/Hold/Sell recommendations from Benzinga, Yahoo Finance, and Finnhub for ATRI.
Price Targets
Wall Street price target analysis for ATRI.
ATRI MoonshotScore
What does this score mean?
The MoonshotScore rates ATRI's growth potential on a scale of 0-100 across multiple factors including innovation, market disruption, financial health, and momentum.
Leadership: David A. Battat
CEO
David A. Battat serves as the CEO of Atrion Corporation, leading a team of 712 employees. His career encompasses extensive experience in the medical device industry, with a focus on strategic leadership and operational excellence. Battat's background includes roles in product development, marketing, and sales, providing him with a comprehensive understanding of the medical device market. He holds advanced degrees in engineering and business administration.
Track Record: Under David Battat's leadership, Atrion Corporation has maintained a steady growth trajectory, focusing on innovation and market expansion. Key achievements include the successful launch of new medical devices and the strengthening of relationships with key customers. Battat has also overseen strategic initiatives to improve operational efficiency and enhance the company's competitive position.
Common Questions About ATRI (Healthcare)
What does Atrion Corporation do?
Atrion Corporation develops, manufactures, and sells medical devices and components for fluid delivery, cardiovascular, and ophthalmology applications. The company's products are used in various medical procedures, including anesthesia, oncology, cardiac surgery, and ophthalmic treatments. Atrion serves a global customer base, selling its products to physicians, hospitals, clinics, and other medical equipment manufacturers. The company's focus on specialized products and niche markets differentiates it from larger medical device companies.
What do analysts say about ATRI stock?
Analyst coverage of Atrion Corporation (ATRI) reflects a generally positive outlook, citing the company's consistent profitability and specialized product portfolio as key strengths. Valuation metrics, such as the P/E ratio of 41.7, suggest that investors anticipate continued earnings growth. Growth considerations include the company's ability to expand into new markets and develop innovative medical devices. However, analysts also note potential risks, such as increased competition and regulatory changes.
What are the main risks for ATRI?
Atrion Corporation faces several risks inherent in the medical device industry. Increased competition from larger medical device manufacturers could erode market share. Regulatory changes impacting medical device approvals could delay product launches and increase compliance costs. Economic downturns could affect hospital budgets, reducing demand for medical devices. Product liability claims related to medical devices could result in significant financial losses. Effective risk management is crucial for Atrion's long-term success.
What are the key factors to evaluate for ATRI?
Atrion Corporation (ATRI) holds an AI score of 38/100 (low). P/E: 41.7x vs the S&P 500's ~20-25x. Not financial advice.
How frequently does ATRI data refresh on this page?
ATRI prices update in real time during U.S. market hours. Fundamentals refresh after quarterly filings; analyst ratings and AI insights update daily; news is aggregated continuously.
What has driven ATRI's recent stock price performance?
Atrion Corporation (ATRI) moves on earnings results, analyst revisions, sector rotation, and market sentiment. Notable catalyst: Specialized product portfolio. See the News tab for the latest drivers. Past performance does not predict future results.
Should investors consider ATRI overvalued or undervalued right now?
Atrion Corporation (ATRI) trades at 41.7x earnings. Compare P/E, P/S, and EV/EBITDA against sector peers for a full view.
What research should beginners do before buying ATRI?
Before investing in Atrion Corporation (ATRI), research these four areas: (1) the company's revenue model and competitive position (see Company Overview), (2) financial health through revenue growth, margins, and cash flow (see MoonshotScore), (3) what Wall Street analysts recommend and their price targets (see Analyst tab), and (4) specific risk factors that could impact the stock (see Risk Factors section).
Disclaimer: This content is for informational purposes only and does not constitute investment advice. Always do your own research and consult a financial advisor.
Official Resources
Data provided for informational purposes only.
- Information is based on available data and may be subject to change.
- Financial metrics are as of 2026-05-10.